Introduction and Objective: DJBL is a novel endoscopic duodenal jejunal liner device for obesity, both with and without diabetes. We aimed to assess risks vs benefits of DJBL.Methods: In 2017 an independent online registry was established by the Association of British Clinical Diabetologists, to collect of safety and efficacy data worldwide.Results: As of January 2025, data had been entered on 1198 patients {age 51.0 ± 12.2 years, 50% male, 77% diabetes, BMI 39.8 ± 8.7 kg/m2} and showed many benefits (Table 1). There were 60 (4.6%) SAEs and 156 (12.0%) less serious AEs (Table 2). All SAE patients made a full recovery and most derived significant benefit.Conclusion: The benefits of DJBL therapy are likely to reduce the complications of diabetes. This international data from the DJBL registry suggests that the benefits greatly outweigh the risks.
R.E.J. Ryder: Speaker’s Bureau; Abbott, AstraZeneca, GI Dynamics. Consultant; GI Dynamics. Other Relationship; Novo Nordisk. Speaker’s Bureau; Besins Healthcare. A. Escalona: None. R. Lopez-Gonzalez: None. C. Lazzara: Consultant; Johnson & Johnson Medical Devices Companies. J. Stein: None. T. Battelino: Advisory Panel; Novo Nordisk. Speaker’s Bureau; Novo Nordisk. Research Support; Novo Nordisk. Advisory Panel; Eli Lilly and Company. Speaker’s Bureau; Eli Lilly and Company. Advisory Panel; Sanofi. Speaker’s Bureau; Sanofi. Research Support; Sanofi. Advisory Panel; Roche Diabetes Care. Speaker’s Bureau; AstraZeneca. Advisory Panel; Abbott. Speaker’s Bureau; Abbott. Research Support; Abbott. Advisory Panel; Dexcom, Inc. Speaker’s Bureau; Dexcom, Inc. Advisory Panel; Medtronic. Speaker’s Bureau; Medtronic. Research Support; Medtronic, Novartis Pharmaceuticals Corporation. A. Ruban: None. J.P. Teare: None. M. Haluzik: Research Support; Sanofi. Advisory Panel; Eli Lilly and Company. Speaker’s Bureau; Novo Nordisk, Abbott. Advisory Panel; AstraZeneca. Speaker’s Bureau; GlaxoSmithKline plc, Amgen Inc. Advisory Panel; Bausch Health. L. Munro: None. H. Frydenberg: None. J.J. McMaster: None. S. Fishman: None. R. Stengel: None. R.V. Cohen: None. J.P. Byrne: Stock/Shareholder; Embla – medical weight management provider. C. de Jonge: None. J. Greve: Consultant; Morphic Medical. J.C. Mason: None. J.R. Bessell: Advisory Panel; Medtronic. L. Kow: None. H. Sourij: Advisory Panel; Eli Lilly and Company. Speaker’s Bureau; Eli Lilly and Company. Research Support; Eli Lilly and Company. Advisory Panel; Boehringer-Ingelheim. Speaker’s Bureau; Daiichi Sankyo. Advisory Panel; Novo Nordisk A/S. Speaker’s Bureau; Novo Nordisk A/S. Advisory Panel; Novartis AG, Amarin Corporation, Amgen Inc. P.N. Pferschy: Stock/Shareholder; Amarin Corporation. R. Drummond: Speaker’s Bureau; Besins. B. McGowan: Speaker’s Bureau; Eli Lilly and Company. Advisory Panel; Novo Nordisk. Speaker’s Bureau; Novo Nordisk. Advisory Panel; AstraZeneca. Stock/Shareholder; reset health. S.A. Amiel: Advisory Panel; Vertex Pharmaceuticals Incorporated. Other Relationship; Vertex Pharmaceuticals Incorporated. Research Support; National Institutes of Health. M. Yadagiri: None. K. Laubner: Speaker’s Bureau; Abbott, Boehringer-Ingelheim, Lilly Diabetes, Sanofi-Aventis U.S., Novo Nordisk, German Diabetes Association, medUpdate, SantisGmbH, Davos Congress. J. Seufert: Speaker’s Bureau; Sanofi-Aventis Deutschland GmbH. Advisory Panel; Boehringer-Ingelheim. Speaker’s Bureau; Boehringer-Ingelheim. Research Support; Boehringer-Ingelheim. Advisory Panel; Lilly Diabetes. Speaker’s Bureau; Lilly Diabetes. Research Support; Lilly Diabetes. Advisory Panel; Novo Nordisk. Speaker’s Bureau; Novo Nordisk. Research Support; Novo Nordisk.
Association of British Clinical Diabetologists
Source link
Leave a Reply